Advertisement: Birketts mid banner
Advertisement: cofinitive mid banner
Advertisement: Allia mid banner
Advertisement: Bar Ellison mid banner property
Advertisement: Featurespace mid banner
Advertisement: Ilux mid banner
Advertisement: Evelyn mid banner
Advertisement: Arm mid banner
Advertisement: CambridgeTechPodcast midbanner
Advertisement: Cambridge Network mid banner
Cambridgeand mid banner advertisement
Advertisement: Wild Knight Vodka
Advertisement: Alan Boswell Group mid banner
Advertisement: SATAVIA mid banner
Advertisement mid banner S-Tech 3
Advertisement: Mogrify mid banner
Barr Ellison Solicitors – commercial property
Advertisement: TTP
Advertisement: CJBS mid banner
Advertisement: SJIP Dirac Building mid-banner
Advertisement: RSM mid banner
Advertisement: Shearline mid banner
Mid banner advertisement: BDO
Advertisement: Simpsons Creative mid banner
Advertisement: SourceBioscience mid banner
Advertisement: Bicycle mid banner
Advertisement: Marshall mid banner
12 October, 2023 - 20:30 By News Desk

Sosei and PharmEnable extend neurological disease drugs hunt

Japanese BioPharma company Sosei Heptares and Cambridge drug discovery firm PharmEnable Therapeutics have expanded a collaboration to apply their respective technologies to combat neurological diseases.

Their alliance is designed to drive novel drug discovery for a second neurological disease target.  

Sosei Heptares, which has research facilities in Cambridge, is known for its expertise in receptor protein structure determination, Structure-Based Drug Design and translational development. 

PharmEnable will apply its proprietary AI-enabled medicinal chemistry platform (chemUNIVERSE) to design highly specific drug leads for further development.

Expanding their 2021 agreement, the companies will jointly conduct and share the costs of the discovery and the development programme and co-own any resulting products equally. 

The companies are already exploiting their complementary capabilities in an ongoing collaboration focused on an initial target receptor, where they have identified promising small molecules with a new binding mode and novel chemotype.

Dr Matt Barnes, President of Sosei group company Heptares Therapeutics and head of UK R & D, said: “Based on our experience working on our initial collaboration target, PharmEnable’s proprietary AI platform has demonstrated a level of success that supports us extending our collaboration. We look forward to applying our SBDD expertise along with PharmEnable’s novel chemistry to further identify high quality molecules.”

Dr. Hannah Sore, founder and CEO of PharmEnable, added: “We are excited to be expanding our partnership with Sosei Heptares to include an additional target. We have demonstrated the complementarity of our platform and Sosei Heptares’ structural insights while working on our first target and we look forward to continuing to work together and applying our technologies to develop life-changing medicines for neurological disease.”

PharmEnable designs high quality novel chemistry to develop highly potent, selective and orally bioavailable new medicines. The company’s proprietary drug discovery platform integrates advanced medicinal chemistry expertise and cutting-edge AI/computational methods to unlock challenging biological targets and deliver highly effective therapies for diseases with significant unmet clinical need. It’s backed by MP Healthcare Venture Management (venture arm of Mitsubishi Tanabe Pharma Group) and a syndicate of experienced life science investors.

Tokyo-headquartered Sosei Heptares is a fully integrated biopharmaceutical company focused on bringing life-changing medicines based on world-class science to patients globally. 

It is advancing a broad and deep pipeline of novel medicines created using its world-leading GPCR-targeted StaR® technology and structure-based drug design platform across multiple therapeutic areas, including neurology, immunology, gastroenterology, and inflammatory diseases. 

It has established multiple value-generating partnerships with world-leading biopharmaceutical companies including AbbVie, Genentech (Roche), GSK, Lilly, Neurocrine Biosciences, Novartis, Pfizer, Sanofi and Takeda. 

Newsletter Subscription

Stay informed of the latest news and features